ABIOMED Announces Schedule of Events for Breakthrough IMPELLA Technology at EuroPCR Conference in Paris

Presentations on ABIOMED's Heart Recovery Technology, includingthe IMPELLA(R) RECOVER LP 2.5, the world's smallest micro-VentricularAssist Device (VAD) will include:

-- On Wednesday, May 17, ABIOMED will host a symposium on "Percutaneous Mechanical Support in High Risk PCI & Cardiogenic Shock, IMPELLA - Your Safety Net in the Cath Lab." The event starts at 4:30 pm in the Palais des Congres, level 3, room 322/323.

-- On Thursday, May 18, Dr. J.P.S. Henriques, Cardiologist at the Academic Medical Center in Amsterdam, will present on "Left Main Stenting with IMPELLA RECOVER 2.5 LP Supporting Poor LV Patients," in room 251 at 8:30 am.

-- Also on Thursday, May 18, Dr. Patrick Hunziker, Cardiologist at the University of Basel in Switzerland, will present on "Where is the 'Point of No Return' in PCI for Acute Myocardial Infarction with CPR?" in room 251 at 3:10 pm.

ABIOMED's IMPELLA RECOVER Technology consists of the IMPELLARecover(R) LP 2.5, the IMPELLA Recover(R) 5.0, the IMPELLA Recover (R)RD, and the IMPELLA Recover (R) LD which are available in Europe underthe CE Mark and are investigational in the United States. Thistechnology has been the subject of more than 20 peer reviewedinternational publications. The Recover(R) LP 2.5 providesinterventional cardiologists with a minimally invasive ventricularunloading catheter, which is inserted percutaneously via the femoralartery into the left ventricle.

ABOUT ABIOMED

Based in Danvers, Massachusetts, ABIOMED, Inc. is a leadingdeveloper, manufacturer and marketer of medical products designed toassist or replace the pumping function of the failing heart. ABIOMEDcurrently manufactures and sells the AB5000(TM) Circulatory SupportSystem and the BVS(R) 5000 Biventricular Support System for thetemporary support of all patients with failing but potentiallyrecoverable hearts. In Europe, ABIOMED offers the IMPELLA(R)RECOVER(R) minimally invasive cardiovascular support systems under CEMark approval. The IMPELLA products are not currently available forsale in the United States. The Company's AbioCor(R) ImplantableReplacement Heart was the subject of an initial clinical trial underan Investigational Device Exemption from the United States Food andDrug Administration. The AbioCor has not been approved for commercialdistribution, and is not available for use or sale outside of theinitial clinical trial. For additional information please visit:www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, includingstatements regarding development of ABIOMED's existing and newproducts, the Company's progress toward commercial growth, and futureopportunities. The Company's actual results may differ materially fromthose anticipated in these forward-looking statements based upon anumber of factors, including uncertainties associated withdevelopment, testing and related regulatory approvals, anticipatedfuture losses, complex manufacturing, high quality requirements,dependence on limited sources of supply, competition, technologicalchange, government regulation, the actual financial effect ofexpensing stock options in the first quarter of fiscal 2007, futurecapital needs and uncertainty of additional financing and other risksand challenges detailed in the Company's filings with the Securitiesand Exchange Commission, including the Annual Report filed on Form10-K. Readers are cautioned not to place undue reliance on anyforward-looking statements, which speak only as of the date of thisRelease. The Company undertakes no obligation to publicly release theresults of any revisions to these forward-looking statements that maybe made to reflect events or circumstances that occur after the dateof this Release or to reflect the occurrence of unanticipated events.